Cox proportional hazards model: multivariable analysis to evaluate factors associated with arthritis persistence
| HR | 95% CI | P value* | |
| TJC33* | 0.88 | 0.62 to 1.26 | 0.50 |
| MD global assessment | 0.96 | 0.87 to 1.05 | 0.33 |
| CDAI | 1.03 | 0.89 to 1.19 | 0.69 |
| Duration ICI therapy (months) | 0.82 | 0.73 to 0.92 | 0.001 |
| Combo versus monotherapy | 0.06 | 0.01 to 0.50 | 0.009 |
| irAEs (0, 1, 2 or more) | 1.05 | 0.44 to 2.52 | 0.90 |
| Melanoma | 0.41 | 0.10 to 1.78 | 0.24 |
| Tumour response (CR/PR vs SD/PD) | 1.51 | 0.34 to 6.63 | 0.59 |
Bold values indicate p-values less than 0.05.
*The outcome of interest was resolution of IA. Therefore, HRs <1 denote factors that associate with persistence of IA.
CDAI, Clinical Disease Activity Index; CR/PR, complete response and partial response; IA, inflammatory arthritis; ICI, immune checkpoint inhibitor; irAEs, immune-related adverse events; SD/PD, stable disease and progressive disease; TJC, tender joint count.